Perspectives in Basic Science

Kidney International (1997) 52, 294–308; doi:10.1038/ki.1997.335

Cell-cycle control and renal disease

Stuart J Shankland1

1Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington, USA

Correspondence: Stuart J Shankland MD, Division of Nephrology, University of Washington, P.O. Box 356521, 1959 NE Pacific Ave, Seattle, Washington 98195, USA. E-mail: stuartjs@u.washington.edu

Received 16 October 1996; Revised 11 December 1996; Accepted 12 December 1996.

Keywords:

cell-cycle, proliferation, cyclins, cyclin dependent kinases, cyclin kinase inhibitors, sclerosis, injury

Top

References

  1. Striker LJ, Doi T, Elliot S, Striker GE: The contribution of glomerular cells to progressive glomerulosclerosis. Semin Nephrol 9:318–328, 1989 | PubMed | ISI | ChemPort |
  2. Abboud HE: Growth factors in glomerulonephritis. Kidney Int 43:252–267, 1993 | Article | PubMed | ISI | ChemPort |
  3. Couser WG, Johnson RJ: Mechanisms of progressive renal disease in glomerulonephritis. Am J Kid Dis 23:193–198, 1994 | PubMed | ChemPort |
  4. Sterzel RB, Schulze-Lohoff E, Marx M: Cytokines and mesangial cells. Kidney Int 39:26–31, 1993
  5. Johnson RJ, Raines EW, Floege J, Yoshimura A, Pritzl P, Alpers C, Ross R: Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med 175:1413–1416, 1992 | Article | PubMed | ISI | ChemPort |
  6. Floege J, Burns MW, Alpers CE, Yoshimura A, Pritzl P, Gordon K, Seifert RA, Bowen-Pope DF, Couser WG, Johnson RJ: Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int 41:297–309, 1992 | PubMed | ISI | ChemPort |
  7. Young BA, Johnson RJ, Alpers CE, Eng E, Gordon K, Floege J, Couser WG: Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 47:935–944, 1995 | Article | PubMed | ISI | ChemPort |
  8. Kliem V, Johnson RJ, Alpers CE, Yoshimura A, Couser WG, Koch KM, Floege J: Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int 49:666–678, 1996 | Article | PubMed | ISI | ChemPort |
  9. Nagle RB, Kneiser MR, Bulger RE, Benditt EP: Induction of smooth muscle characteristics in renal interstitial fibroblasts during obstructive nephropathy. Lab Invest 29:422–427, 1974
  10. Johnson GL, Vaillancourt RR: Sequential protein kinase reactions controlling cell growth and differentiation. Curr Opin Cell Biol 6:230–238, 1994 | Article | PubMed | ISI | ChemPort |
  11. Pardee AB: G1 events and regulation of cell proliferation. Science 246:603–608, 1989 | Article | PubMed | ISI | ChemPort |
  12. Norbury C, Nurse P: Animal cell cycles and their control. Annu Rev Biochem 61:441–471, 1992 | Article | PubMed | ISI | ChemPort |
  13. Zetterberg A, Larson O, Wiman KG: What is the restriction point? Curr Opin Cell Biol 7:835–842, 1995 | Article | PubMed | ISI | ChemPort |
  14. Murray A, Hunt T: The Cell Cycle. New York, W.H. Freeman and Co., 1993
  15. Morgan DO: Principles of CDK regulation. Nature 374:131–134, 1995 | Article | PubMed | ISI | ChemPort |
  16. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Develop 9:1149–1163, 1995 | PubMed | ChemPort |
  17. Hockenbery D: Defining apoptosis. Am J Pathol 146:16–19, 1995 | PubMed | ISI | ChemPort |
  18. Meikrantz W, Schegal R: Apoptosis and the cell cycle. J Cell Biochem 58:160–174, 1995 | Article | PubMed | ISI | ChemPort |
  19. Smith JR, Pereira-Smith OM: Replicative senescence: Implications for in vivo aging and tumor suppression. Science 273:63–67, 1996 | Article | PubMed | ISI | ChemPort |
  20. Weinberg RA: HOW cancer arises. Sci Am Sept: 62–70, 1996
  21. Takase K, Terada N, Lucas JJ, Gelfand EW: Control of cell cycle entry and progression in mitogen-stimulated human B lymphocytes. J Cell Physiol 162:246–255, 1995 | Article | PubMed | ChemPort |
  22. Lees E: Cyclin dependent kinase regulation. Curr Opin Cell Biol 7:773–780, 1995 | Article | PubMed | ISI | ChemPort |
  23. Herber B, Truss M, Beato M, Muller R: Inducible regulatory elements in the human cyclin Dl promoter. Oncogene 9:2105–2107, 1994 | PubMed | ISI | ChemPort |
  24. Brooks AR, Shiffman D, Chan CS, Brooks EE, Milner PG: Functional analysis of the human cyclin D2 and cyclin D3 promoters. J Biol Chem 271:9090–9099, 1996 | Article | PubMed | ISI | ChemPort |
  25. Henglein B, Chenivesse X, Wang J, Eick D, Brechot C: Structure and cell cycle-regulated transcription of the human cyclin A gene. Proc NatlAcad Sci USA 91:5490–5494, 1994 | ChemPort |
  26. Pines J: Cyclins and cyclin-dependent kinases: A biochemical view. Biochem J 308:697–711, 1995 | PubMed | ISI | ChemPort |
  27. Polyak K, Kato J, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A: p27 kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Develop 8:9–22, 1994 | PubMed | ChemPort |
  28. Lee M-H, Reynisdottir I, Masague J: Cloning of p57Kip2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Develop 9:639–649, 1995 | PubMed | ISI | ChemPort |
  29. Hannon GJ, Beach D. p15INK4b is a potential effector of TGF-beta induced cell cycle arrest. Nature 371:257–261, 1994 | Article | PubMed | ISI | ChemPort |
  30. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704–707, 1993 | Article | PubMed | ISI | ChemPort |
  31. Chan FKM, Zhang J, Cheng L, Shapiro DN, Winoto A: Identifiation of human and mouse p19, a novel CDK4and CDK6 inhibitor with homology to p16 INK4. Mol Cell Biol 15:2682–2688, 1995 | PubMed | ISI | ChemPort |
  32. Kobayashi H, Stewart E, Poon R, Adamczewski JP, Gannon J, Hunt T: Identification of the domains in cyclin A required for binding to and activiation of, p34cdc2 and p32cdk2 protein kinase subunits. Mol Biol Cell 3:1279–1294, 1992 | PubMed | ISI | ChemPort |
  33. Sherr CJ: Mammalian G1 cyclins. Cell 73:1059–1065, 1993 | Article | PubMed | ISI | ChemPort |
  34. Lew DJ, Dulic V, Reed SI: Isolation of three novel human cyclins by rescue of G1 cyclin (CIn) function in yeast. Cell 66:1197–1206, 1991 | Article | PubMed | ISI | ChemPort |
  35. Kato J, Sherr CJ: Inhibition of granulocyte differentiation by G1 cyclins D2 and D3 but not D1. Proc Natl Acad Sci USA 90:11513–11517, 1993 | Article | PubMed | ChemPort |
  36. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J, Livingston DM: Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73:487–497, 1993 | Article | PubMed | ISI | ChemPort |
  37. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ: Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Develop 7:331–342, 1993 | PubMed | ChemPort |
  38. Xiong Y, Zhang H, Beach D: D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71:505–514, 1992 | Article | PubMed | ISI | ChemPort |
  39. Sewing A, Burger C, Brusselbach S, Schalk C, Lubibello FC, Muller R: Human cyclin Dl encodes a labile nuclear protein whose synthesis is directly induced by growth factors and suppressed by cAMP. J Cell Sci 104:545–554, 1993 | PubMed | ISI | ChemPort |
  40. Won K, Xiong Y, Beach D, Gilman MZ: Growth-regulated expression of D-type cyclin genes in human diploid fibroblasts. Proc Natl Acad Sci USA 89:9910–9914, 1992 | Article | PubMed | ChemPort |
  41. Geng Y, Weinberg RA: Transforming growth factor beta effects on expression of G1 cyclins and cyclin-dependent kinases. Proc Natl Acad Sci USA 90:10315–10319, 1993 | Article | PubMed | ChemPort |
  42. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G: Cyclin D1 is a protein required for cell cycle progression in G1. Genes Develop 7:812–821, 1993 | PubMed | ChemPort |
  43. Pagano M, Pepperkok R, Lukas J, Baldin V, Ansorge W, Bartek J, Draetta G: Regulation of the cell cycle by cdk2 protein kinase in cultured human fibroblasts. J Cell Biol 121:101–111, 1993 | Article | PubMed | ISI | ChemPort |
  44. Quelle DE, Ashmun RA, Shurtleff SA, Kato J-Y, Bar-Sagi D, Roussel MF, Sherr CJ: Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Develop 7:1559–1571, 1993 | PubMed | ChemPort |
  45. Matsushime H, Roussel MF, Ashmun RA, Sherr CJ: Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 65:701–713, 1992 | Article |
  46. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M: Human cyclin E, a nuclear protein essentail for the G1-to-S phase transition. Mol Cell Biol 15:2612–2624, 1995 | PubMed | ISI | ChemPort |
  47. Gong JG, Ardelt B, Traganos F, Darzynkiewicz Z: Unscheduled expression of cyclin B1 and cyclin E in several leukemic and solid tumor cell lines. Cancer Res 54:4285–4288, 1994 | PubMed | ISI | ChemPort |
  48. Ohtsubo M, Roberts JM: Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science 259:1908–1912, 1993 | Article | PubMed | ISI | ChemPort |
  49. Koff A, Ohtsuki M, Polyak K, Roberts JM, Massague J: Negative regulation of G1 in mammalian cells: Inhibition of cyclin E-dependent kinase by TGF-beta. Science 260:536–539, 1993 | Article | PubMed | ISI | ChemPort |
  50. Eblen ST, Fautsch MP, Burnette RJ, Joshi P, Leof EB: Cell cycle-dependent inhibition of p34cdc2 synthesis by transforming growth factor beta1 in cycling epithelial cells. Cell Growth Differ 5:109–116, 1994 | PubMed | ChemPort |
  51. Bates S, Parry D, Boetta L, Vousden K, Dickson C, Peters C: Absence of cyclin D/CDK4 complexes in cells lacking functional retinoblastoma protein. Oncogene 9:1633–1640, 1994 | PubMed | ISI | ChemPort |
  52. Rogers S, Wells R, Rechsteiner M: Amino acid sequences common to rapidly degraded proteins: The PEST hypothesis. Science 234:364–368, 1986 | Article | PubMed | ISI | ChemPort |
  53. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G: Cyclin A is required at two points in the human cell cycle. EMBO J 11:961–971, 1992 | PubMed | ISI | ChemPort |
  54. Girard F, Strausfeld U, Fernandez A, Lamb N: Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 67:1169–1179, 1991 | Article | PubMed | ISI | ChemPort |
  55. Guadagno TM, Ohtsubo M, Roberts JM, Assoian RK: A link between cyclin A expression and adhesion-dependent cell cycle progression. Science 262:1572–1575, 1993 | Article | PubMed | ISI | ChemPort |
  56. Devoto SH, Mudryji M, Pines J, Hunter T, Nevins JR: A cyclin A-protein kinase complex possesses sequence-specific DNA binding activity: p33cdk2 is a component of the E2F-Cyclin A complex. Cell 68:167–176, 1992 | Article | PubMed | ISI | ChemPort |
  57. Shirodkar S, Ewen M, Decaprio JA, Morgon J LD, Chittenden T: The transcription factor E2F interacts with the retinoblastoma product and p107-cyclin A complex in a cell cycle-regulated manner. Cell 68:157–166, 1992 | Article | PubMed | ISI | ChemPort |
  58. Yoshizumi M, Hsieh C-M, Zhou F, Tsai J, Patterson C, Perella MA, Lee M: The ATF site mediates downregulation of the cyclin A gene during contact inhibtion in vascular endothelial cells. Mol Cell Biol 15:3266–3272, 1995 | PubMed | ChemPort |
  59. Reddy KB, Hocevar BA, Howe PH: Inhibition of G1 phase cyclin dependent kinases by transforming growth factor beta1. J Cell Biochem 56:418–425, 1994 | Article | PubMed | ISI | ChemPort |
  60. Satterwhite DJ, Aakre ME, Gorska AE, HLM: Inhibition of cell growth by TGFbeta1 is associated with inhibition of B-myb and cyclin A in both BALB/MK and Mv1Lu cells. Cell Growth Diff 5:789–799, 1994 | PubMed | ChemPort |
  61. Feng XH, Filvaroff EH, Derynck R: Transforming growth factor-beta (TGF-beta)-induced down-regulation of cyclin A expression requires a functional TGF-beta receptor complex. J Biol Chem 270:24237–24245, 1995 | Article | PubMed | ISI | ChemPort |
  62. Coleman TR, Dunphy WG: Cdc2 regulatory factors. Curr Opin Cell Biol 6:877–882, 1994 | Article | PubMed | ISI | ChemPort |
  63. Pines J, Hunter T: Isolation of a human cyclin cDNA: Evidence for cyclin mRNA and protein regulation in cell cycle and for interaction with P34cdc2. Cell 58:833–846, 1989 | Article | PubMed | ISI | ChemPort |
  64. Stewart E, Kobayashi H, Harrison D, Hunt T: Destruction of Xenopus cyclins A, B2, but not B1, requires binding to p34cdc2. EMBO J 13:584–594, 1994 | PubMed | ISI | ChemPort |
  65. Glotzer M, Murray AW, MWK: Cyclin is degraded by the ubiquitin pathway. Nature 1349:132–138, 1991 | Article |
  66. Solomon MJ, Harper JW, Shuttleworth J: CAK, the p34cdc2 activation kinase, contains a protein identical or closely related to p40MO15. EMBO J 12:3133–3142, 1993 | PubMed | ISI | ChemPort |
  67. Debondt HL, Rosenblatt J, Jancarik J, Jons HD, Morgon DO: Crystal structure of cyclin dependent kinase 2. Nature 363:595–602, 1993 | Article | PubMed | ISI | ChemPort |
  68. Lees EM, Harlow E: Sequences within the conserved cyclin box of human cyclin A are sufficient for binding to and activation of cdc2 kinase. Mol Cell Biol 13:1194–1210, 1993 | PubMed | ChemPort |
  69. Lorca T, Labbe J, Devalult A: Dephosphorylation of cdc2 on threonine-161 is required for cdc2 kinase inactivation and normal anaphase. EMBO J 11:2381–2390, 1992 | PubMed | ISI | ChemPort |
  70. Draetta B: cdc2 activation: The interplay of cyclin binding and Thrl61 phosphorylation. Trend Cell Biol 3:287–289, 1993 | Article |
  71. Meyerson M, Harlow E: Identification of Gl kinase activity for CDK6, a novel cyclin D partner. Mol Cell Biol 14:2077–2086, 1994 | PubMed | ISI | ChemPort |
  72. Nurse P: Universal control mechanism regulating onset of M-phase. Nature 344:503–508, 1990 | Article | PubMed | ISI | ChemPort |
  73. Ewen ME, Sluss HK, Whitehouse LL, Livingston DM: TGFbeta inhibition of CDK4 synthesis is linked to cell cycle arrest. Cell 74:1009–1020, 1993 | Article | PubMed | ISI | ChemPort |
  74. Russo AA, Jeffrey PD, Patten AK, Massague J, Pavletich NP: Crystal structure of the p27Kipl cyclin-dependent kinase inhibitor bound to the cyclin A-CDK2 complex. Nature 382:325–331, 1996 | Article | PubMed | ISI | ChemPort |
  75. Shiffman D, Brooks EE, Brooks AR, Chan CS, Milner PG: Characterization of the human cyclin-dependent kinase 2 gene. J Biol Chem 271:12199–12204, 1996 | PubMed | ChemPort |
  76. Herschman HR: Primary response genes induced by growth factors and tumor promoters. Annu Rev Biochem 60:281–319, 1991 | Article | PubMed | ISI | ChemPort |
  77. Nigg EA: Targets of cyclin-dependent kinases. Curr Opin Cell Biol 5:187–193, 1993 | Article | PubMed | ChemPort |
  78. Weinberg RA: The retinoblastoma protein and the cell cycle. Cell 81:323–330, 1995 | Article | PubMed | ISI | ChemPort |
  79. Laiho M, Decaprio JA, Ludlow JW, Livingston DM, Massague J: Growth inhibition by TGF-beta linked to suppression of retinoblas toma protein phosphorylation. Cell 62:175–185, 1990 | Article | PubMed | ISI | ChemPort |
  80. La Thangue NB: DP and E2F proteins: Components of a het-erodimeric transcription factor implicated in cell cycle control. Curr Opin Cell Biol 6:443–450, 1994 | Article | PubMed | ChemPort |
  81. Nevins JR: E2F; A link between the Rb tumor suppressor protein and viral oncoproteins. Science 258:424–428, 1992 | Article | PubMed | ISI | ChemPort |
  82. Elledge SJ, Harper JW: CDK inhibitors: On the threshold of checkpoints and development. Curr Opin Cell Biol 6:847–852, 1994 | Article | PubMed | ISI | ChemPort |
  83. Peter M, Herskowitz I: Joining the complex: Cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 79:181–184, 1994 | Article | PubMed | ISI | ChemPort |
  84. Polyak K, Lee M-H, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massaue J: Cloning of p27Kip1, a cyclin-dependent inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59–66, 1994 | Article | PubMed | ISI | ChemPort |
  85. Cordon-Cardo C: Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 147:545–560, 1995 | PubMed | ChemPort |
  86. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–825, 1993 | Article | PubMed | ChemPort |
  87. Datto MB, Panus JF, Howe DJ, Xiong Y, Wang X-F: Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 92:5545–5549, 1995 | Article | PubMed | ChemPort |
  88. Elbendary A, Berchuck A, Davis P, Havrilesky L, Bast RC, Iglehart D, Marks JR: Transforming growth factor beta1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Diff 5:1301–1307, 1994 | PubMed | ChemPort |
  89. Mazars P, Barboule N, Baldin V, Vidal S, Ducommun B, Valette A: Effects of TGF-beta1 on the cell cycle regulation of human breast adenocarcinoma (MCF-7) cells. FEBS Lett 362:295–300, 1995 | Article | PubMed | ISI | ChemPort |
  90. Li C-Y, Suardet L, Little JB: Potential role of WAF1/Cip1/p21 as a mediator of TGF-beta cytoinhibitory effect. J Biol Chem 270:4971–4974, 1995 | Article | PubMed | ISI | ChemPort |
  91. Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olson EN, Harper JW, Elledge SJ: p53-Independent expression of p21Cip1 in muscle and other terminally diffentiating cells. Science 267:1024–1027, 1995 | Article | PubMed | ISI | ChemPort |
  92. Steinman RA, Hoffman B, Iro A, Guillouf C, Lieberman DA, El-Houseini ME: Induction of p21 (WAF1/CIP1) during diffentiation. Oncogene 9:3389–3396, 1994 | PubMed | ISI | ChemPort |
  93. Missero C, Calautti E, Eckner R, Chin J, Tsai LH, Livingston DM, Dotto GP: Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation. Proc Natl Acad Sci USA 92:5451–5455, 1995 | Article | PubMed | ChemPort |
  94. Chin YE, Kitagawa M, Su W-CS, You Z-H, Iwamoto Y, Fu Xi-Y: Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 Waf1/Cip1 mediated by STAT1. Science 272:719–722, 1996 | Article | PubMed | ISI | ChemPort |
  95. Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee M, Massague J, Crabtree GR, Roberts JM: Interleukin-2-mediated elimination of the p27 kip1 cyclin-dependent kinase inhibitor pre vented by rapamycin. Nature 372:570–573, 1994 | Article | PubMed | ISI | ChemPort |
  96. Kato J, Matsuoka K, Polyak K, Massague J, Sherr CJ: Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase-4 activating kinase. Cell 79:487–496, 1994 | Article | PubMed | ISI | ChemPort |
  97. Hirama T, Koeffler HP: Role of cyclin dependent kinase inhibitors in the development of cancer. Blood 86:841–854, 1995 | PubMed | ISI | ChemPort |
  98. Tam SW, Shay JW, Pagano M: Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16INK4. Cancer Res 54:5816–5820, 1994 | PubMed | ISI | ChemPort |
  99. Guan K-L, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, Matera AG, Xiong Y: Growth suppression by p18, a p16INK4/MTS1 and p14INK4/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Develop 8:2939–2952, 1994 | PubMed | ChemPort |
  100. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge J: The p21 cdk-interacting protein Cip1 is a potent inhibitor of Gl cyclin-dependent kinases. Cell 75:805–816, 1993 | Article | PubMed | ISI | ChemPort |
  101. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai L, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell E, Fox MP, Wei N: Inhibition of cyclin dependent kinases by p21. Mol Biol Cell 6:387–400, 1995 | PubMed | ISI | ChemPort |
  102. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Sj E: p57Kip2, a structurally distinct member of the p21Cip1 CDK inhibitor family, is a candidate tumor suppressor gene. Genes Develop 9:650–662, 1995 | PubMed | ChemPort |
  103. Aprelikova O, Xiong Y, Liu ET: Both p16 and p21 families of CDK inhibitors block CDK phosphorylation by the CDK activiating kinase (CAK). J Biol Chem 270:18195–18197, 1995 | Article | PubMed | ISI | ChemPort |
  104. Chen IT, Akamatsu M, Smith ML, Lung F, Duba D, Roleer PP, Fornace AJ Jr: Charaterization of p21 Cip1/Waf1 peptide domains required for cyclin E/CDK2 and PCNA interaction. Oncogene 12:595–607, 1996 | PubMed | ISI | ChemPort |
  105. Luo Y, Hurwitz J, Massague J: Cell-cycle inhibition by independent CDK and PCNA binding domains in p21CIP1. Nature 375:159–161, 1995 | Article | PubMed | ISI | ChemPort |
  106. Xiong Y, Hannon GJ, Zhang GJ, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366:701–704, 1993 | Article | PubMed | ISI | ChemPort |
  107. Gu Y, Turck CW, Morgon DO: Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366:707–710, 1993 | Article | PubMed | ISI | ChemPort |
  108. Noda A, Ning Y, Venable SF, Pereira-Smiths OM, Smith JR: Cloning of senescent cell-derived inhibitors of DNA synthesis using expression vectors. Exp Cell Res 211:90–98, 1994 | Article | PubMed | ISI | ChemPort |
  109. Li R, Waga S, Hannon GJ, Beach D, Stillman B: Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371:534–537, 1994 | Article | PubMed | ISI | ChemPort |
  110. Chen J, Jackson PK, Kirschner MW, Dutta A: Seperate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374:386–388, 1995 | Article | PubMed | ISI | ChemPort |
  111. Prelich G, Tan CK, Kostura M, Mathews MB, So AG, Downey KM, Stillman B: Functional identity of proliferating cell nuclear antigen and a DNA polymerase-d auxiliary protein. Nature 326:517–520, 1987 | Article | PubMed | ISI | ChemPort |
  112. Shivji MKK, Kenny MK, Wood RD: Proliferating cell nuclear antigen is required for DNA excision repair. Cell 69:367–374, 1992 | Article | PubMed | ISI | ChemPort |
  113. Chen J, Peters R, Saha P, Lee P, Theodoras A, Pagano M, Wagner G, Dutta AA: 39 amino acid fragment of the cell cycle regulator p21 is sufficient to bind PCNA and partially inhibit DNA replication in vivo. Nucl Acid Res 24:1727–1733, 1996 | ChemPort |
  114. Waga S, Hannon GJ, Beach D, Stillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574–578, 1994 | Article | PubMed | ISI | ChemPort |
  115. Chang MW, Barr E, Lu MM, Barton K, Leidin JM: Adenovirus-mediated over-expression of the cyclin/cyclin dependent kinase in hibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Inveet 96:2260–2268, 1995 | ChemPort |
  116. Dulic V, Kaufmann WK, Wilson SJ, Tisty TD, Lees E, Harper JW, Elledge SJ, Reed SI: p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013–1023, 1994 | Article | PubMed | ISI | ChemPort |
  117. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackmant, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B: WAF1/Cip1 is induced in p53 mediated G1 arrest and apoptosis. Cancer Res 54:1169–1174, 1994 | PubMed | ChemPort |
  118. Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D, Lassar AB: Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by myoD. Science 267:1018–1021, 1995 | Article | PubMed | ISI | ChemPort |
  119. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P: Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82:675–684, 1995 | Article | PubMed | ISI | ChemPort |
  120. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ: Radiation-induced cell cycle arrest comprimised by p21-deficiency. Nature 377:552–557, 1995 | Article | PubMed | ISI | ChemPort |
  121. Wu H, Wade M, Krall L, Grisham J, Xiongy Y VDT: Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression, postnatal liver development, and regeneration. Genes Develop 10:245–260, 1996 | PubMed | ChemPort |
  122. Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78:67–74, 1994 | Article | PubMed | ISI | ChemPort |
  123. Hengst L, Reed SI: Translational control of p27 accumulation during the cell cycle. Science 271:1861–1864, 1996 | Article | PubMed | ISI | ChemPort |
  124. Pagano M, Tam SW, Theodoras AM, Beer-Romera P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M: Role of the ubiquitin-proteosome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682–685, 1995 | Article | PubMed | ISI | ChemPort |
  125. Coats S, Flanagan WM, Nourse J, Roberts JM: Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 272:877–880, 1996 | Article | PubMed | ISI | ChemPort |
  126. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai L, Broudy V, Perimutter RM, Kaushansky K, Roberts JM: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27Kip1-deficient mice. Cell 85:733–744, 1996 | Article | PubMed | ISI | ChemPort |
  127. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA, Koff A: Enhanced growth in mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell 85:721–732, 1996 | Article | PubMed | ISI | ChemPort |
  128. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K: Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707–720, 1996 | Article | PubMed | ISI | ChemPort |
  129. Hirai H, Roussel MF, Kato J-Y, Ashmun RA SC Novel INK4 proteins. p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol CellBiol 12:503–511, 1995
  130. Marx J: New tumor suppressor may rival p53. Science 264:344–345, 1994 | Article | PubMed | ChemPort |
  131. Klahr S, Schreiner G, Ichikawa I: Progression in renal disease. N Engl J Med 318:1657–1666, 1988 | PubMed | ISI | ChemPort |
  132. Floege J, Eng E, Young BA, Couser WG, Johnson RJ: Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis. Kidney Int 43:369–380, 1993 | Article | PubMed | ISI | ChemPort |
  133. Fukui M Nt, Ebihara I, Nagaoka I, Tomino Y: Low-protein diet attenuates increased gene expression of platelet-derived growth factor and transforming growth factor-beta in experimental glomerular scleosis. J Lab Clin Med 121:224–234, 1992
  134. Okuda S, Nakamura T, Yamamoto T, Ruoslahti E, Border WA: Dietery protein restriction rapidly reduces transforming growth factor beta1 expression in experimental glomerulonephritis. Proc Natl Acad Sci USA 88:9765–9769, 1991 | Article | PubMed | ChemPort |
  135. Floege J, Johnson RJ, Gordon KL, Iida H, Pritzl P, Yoshimura A, Campbell C, Alpers CE, Couser WG: Increased synthesis of extracellular matrix in mesangial proliferative nephritis. Kidney Int 40:477–488, 1991 | PubMed | ISI | ChemPort |
  136. Floege J, Johnson RJ, Alpers CE, Fatemi-Nainie S, Richardson CA, Gordon K, Couser WG: Visceral glomerular epithelial cells can proliferate in vivo and synthesize platelet-derived growth factor p-chain. Am J Pathol 142:637–650, 1993 | PubMed | ISI | ChemPort |
  137. Kriz W, Hahnel B, Rosener S, Elger M: Long-term treatment of rats with FGF-2 results in focal segmental glomerulosclerosis. Kidney Int 48:1435–1450, 1995 | Article | PubMed | ISI | ChemPort |
  138. Seyer-Hansen K: Renal hypertrophy in experimental diabetes mellitus. Kidney Int 23:643–646, 1983 | PubMed | ChemPort |
  139. Fine L: The biology of renal hypertrophy. (Editorial Review) Kidney Int 29:619–634, 1986 | PubMed | ISI | ChemPort |
  140. Ishidoya S, Morrissey J, Mccracken R, Reyes A, Klahr S: Angiotensin II receptor antagonist ameliorates renal tubulointersti-tial flbosis caused by unilateral ureteral obstruction. Kidney Int 47:1285–1294, 1995 | Article | PubMed | ISI | ChemPort |
  141. Yamada T, Terada Y, Nakashima O, Sasaki S, Marumo F: Regulation of G1 cyclin and cell cycle inhibitors in experimental glomerulonephritis. (abstract) J Am Soc Nephrol 7:1726, 1996
  142. Shankland SJ, Hugo C, Coats SR, Nangaku M, Pichler RH, Gordon KL, Pippin J, Roberts JM, Couser WG, Johnson RJ: Changes in cell cycle protein expression during experimental mes angial proliferative glomerulonephritis. Kidney Int 50:1230–1239, 1996 | Article | PubMed | ISI | ChemPort |
  143. Shankland SJ, Floege J, Thomas SE, Nangaku M, Hugo C, Pippin J, Henne K, Hockenberry DM, Johnson RJ, Couser WG: Cyclin kinase inhibitors are increased during experimental membranous nephropathy: Potential role in limiting glomerular epithelial cell proliferation in vivo. Kidney Int 52:404–413, 1997 | Article | PubMed | ISI | ChemPort |
  144. Shankland SJ, Hamel PA, Scholey JW: Cyclin and cyclin-dependent kinase expression in the glomeruli of normal, diabetic and renal-ablated rats. (abstract) J Am Soc Nephrol 5:701, 1994
  145. Shankland SJ, Hamel PA, Scholey JW: Cyclin and cyclin dependent kinase expression in the remnant glomerulus. J Am Soc Nephrol 8:368–375, 1997 | PubMed | ISI | ChemPort |
  146. Park SK, Kang SK, Lee DY, Kang MJ, Kim SH, Koh GY: Alterations of cyclin and cyclin-dependent kinases during renal development and pathologic growth. (abstract) J Am Soc Nephrol 6:114, 1995
  147. Terada Y, Shimizu A, Sasaki S, Yamanaka N, Marumo F Regulations of G1 cyclin and cell cycle inhibitors during recovery from acute renal ischemia. (abstract) J Am Soc Nephrol 6:992, 1995
  148. Park SK, Kang MJ, Kim I, Terhune A, Koh GY: Temporal expression of cyclin dependent kinase inhibitors during renal development and hypertrophic renal growth. (abstract) J Am Soc Nephrol 7:1663, 1996
  149. Price PM, Megyesi J, Udvarhelyi N, Safirstein R: Synthesis of mRNA for the p21, a protein associated with cell-cycle arrest, senescence and terminal differentiation following acute renal failure. (abstract) J Am Soc Nephrol 6:114, 1995
  150. Morrissey JJ, Ishidoya S, Mccracken R, Klahr S: The effect of ACE inhibitors on the expression of matrix genes and the role of p53 and p21 (WAF1) in experimental renal fibrosis. Kidney Int 49:(Suppl 54):S83–S87, 1996 | ISI |
  151. Shankland SJ, Hugo CH, Coats SR, Nangaku M, Gordon KL, Pippin J, Roberts JM, Couser WG, Johnson RJ: Cyclin kinase inhibitors: Potential regulators of mesangial cell (MC) proliferation in vivo. (abstract) J Am Soc Nephrol 6:776, 1995
  152. Terada Y, Yamada T, Sasaki S, Marumo F: Overexpression of cyclin D1 and cell cycle inhibitors (p16INK4 and p21cip1) using adenovirus vectors regulates proliferation in rat mesangial cells. J Am Soc Nephrol 8:51–60, 1997 | PubMed | ISI | ChemPort |
  153. Schoecklmann HO, Rupprecht HD, Zauner I, Sterzel RB: TGF-beta1 induced cell cycle arrest in renal mesangial cells involves inhibition of cyclin E-CDK2 activation and retinoblastoma protein phosphorylation. Kidney Int 51:1228–1236, 1997 | Article | PubMed | ISI | ChemPort |
  154. Shankland SJ, Pippin J, Flanagan M, Coats SR, Nangaku M, Gordon KL, Roberts JM, Couser WG, Johnson RJ: Mesangial cell proliferation mediated by PDGF and bFGF is determined by levels of the cyclin kinase inhibitor p27Kip1. Kidney Int 51:1088–1099, 1997 | Article | PubMed | ISI | ChemPort |
  155. Huang H, Wang H: Cyclin D1, Cdk4 expression and cyclin D1 upregulation by endothelin-1 in rat mesangial cells. (abstract) J Am Soc Nephrol 7:1658, 1996
  156. Inoshita S, Terada Y, Ymamda T, Nakashima O, Sasaki S, Marumo F: Mitogenic signaling of endothelin-1 is regulated by cyclin D1, p16 and the phosphorylation of retinoblastoma gene product in rat mesangial cells. (abstract) J Am Soc Nephrol 7:1564, 1996
  157. Terada Y, Yamada T, Nakashima O, Sasaki S, Marumo F: TGF-beta and simvastatin inhibit rat mesangial cell proliferation via different CDK inhibitor in vitro and in anti-Thyl nephritis. (abstract) J Am Soc Nephrol 7:1722, 1996
  158. Pabst R, Sterzel RB: Cell renewal of glomerular cell types in normal rats. An autoradiographic analysis. Kidney Int 24:626–631, 1983 | PubMed | ISI | ChemPort |
  159. Johnson RJ, Pritzl P, Iada H, Alpers CE: Platelet-complement interactions in mesangial proliferative nephritis in the rat. Am J Pathol 138:313–321, 1991 | PubMed | ISI | ChemPort |
  160. Floege J, Eng E, Young BA, Alpers CE, Barrett TB, Bowen-Pope DF, Johnson RJ: Infusion of platelet-derived growth factor or basic fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats. J Clin Invest 92:2952–2962, 1993 | PubMed | ISI | ChemPort |
  161. Shankland SJ, Hamel PA, Scholey JW: Phosphorylation of reti noblastoma protein in glomeruli of normal, diabetic and renal-ablated rats. (abstract) J Am Soc Nephrol 5:701, 1994
  162. Yamada T, Terada Y, Shimizu A, Sasaki, Yamanaka N, Murumo F: Regulations of G1 cyclin and cell cycle inhibitors during recovery from acute renal ischemia. (abstract) J Am Soc Nephrol 6:992, 1995
  163. Franch HA, Shay JW, Alpern RJ, Preisig PA: Involvement of pRb family in TGFbeta-dependent epithelial cell hypertrophy. J Cell Biol 129:245–254, 1995 | Article | PubMed | ISI | ChemPort |
  164. Franch HA, Alpern RJ, Preisig PA: TGFbeta converts EGF-induced hyperplasia to hypertrophy by inhibiting CDK2/cyclin E kinase activity. (abstract) J Am Soc Nephrol 6:767, 1995
  165. Yoshizumi M, Lee W-S, Hsieh C-M, Tsai J-C, Li J, Perrella MA, Patterson C, Endege WO, Schegel R, Lee M-E: Disappearance of cyclin A correlates with permanent withdrawal of cardiomyocytes from the cell cycle in human and rat hearts. J Clin Invest 95:2275–2280, 1995 | PubMed | ISI | ChemPort |
  166. Yamamoto T, Noble NA, Miller DE, Border WA: Sustained expression of TGF-beta1 underlies development of progressive kidney fibrosis. Kidney Int 45:916–927, 1994 | Article | PubMed | ISI | ChemPort |
  167. Price PM, Megyesi J, Udvarhelyi N, Safirstein R: Induction of terminal differentiation in kidney tubules by the p21 cyclin dependent kinase (CDK) inhibitor. (abstract) J Am Soc Nephrol 7:1603, 1996
  168. Nagata M, Yamaguchi Y, Ito K: LOSS of mitotic activity and the expression of vimentin in glomerular epithelial cells of developing human kidneys. Anat Embryol 187:275–279, 1993 | PubMed | ISI | ChemPort |
  169. Floege J, Kriz W, Schulze M, Susani M, Kerjaschki D, Mooney A, Couser WG, Koch KM: Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephrology. J Clin Invest 96:2809–2819, 1996 | ISI |
  170. Shankland SJ, Pippin J, Pichler RH, Gordon KL, Friedman S, Gold LI, Johnson RJ, Couser WG: Differential expression of transforming growth factor-beta isoforms and receptors in experimental membranous nephropathy. Kidney Int 50:116–124, 1996 | Article | PubMed | ISI | ChemPort |
  171. Adler S, Chen X, Eng B: Control of rat glomerular epithelial cell growth in vitro. Kidney Int 37:1048–1054, 1990 | Article | PubMed | ISI | ChemPort |
  172. Border WA, Noble NA: Transforming growth factor 18 in tissue fibrosis. N Engl J Med 331:1286–1292, 1994 | Article | PubMed | ISI | ChemPort |
  173. Sharma K, Ziyadeh FN: The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol 266:F829–F842, 1994 | PubMed | ISI | ChemPort |
  174. Choi ME, Eung-Gook K, Huang Q, Ballerman BJ: Rat mesangial cell hypertrophy in response to transforming growth factor-131. Kidney Int 44:948–958, 1993 | Article | PubMed | ISI | ChemPort |
  175. Preisig PA, Franch HA: Renal epithelial hyperplasia and hyper trophy. Semin Nephrol 15:327–340, 1995 | PubMed | ISI | ChemPort |
  176. Liu B, Preisig PA: TGFbeta-mediated conversion of EGF-induced hyperplasia to hypertrophy involves cyclin E, but not cyclin D kinase regulation, and is dependent on cells being in a confluent state. (abstract) J Am Soc Nephrol 7:1661, 1996
  177. Terada Y, Yamada T, Nakashima O, Sasaki S, Marumo F: Angiotensin II induced p21CIP1 via JAK2-STAT1 pathway and caused hypertrophy in proximal tubule cells. (abstract) J Am Soc Nephrol 7:1776, 1996
  178. Wolf G, Stahl RAK: Angiotensin II (All) stimulated hypertrophy of LLC-PK1 cells depends on the induction of the cyclin-dependent kinase inhibitor p27Kip1. Kidney Int 50:2112–2119, 1996 | Article | PubMed | ISI | ChemPort |
  179. Sharma K, Jin Y, Guo J, Ziyadeh FN: Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and enhanced extracellular mtrix gene expression in STZ-induced diabetic mice. Diabetes 45:522–530, 1996 | Article | PubMed | ISI | ChemPort |
  180. Shankland SJ, Scholey JW: Expression of transforming growth factor-beta1 during diabetic renal hypertrophy. Kidney Int 46:430–442, 1994 | Article | PubMed | ISI | ChemPort |
  181. Megyesi J, Udvarhelyi N, Safirstein RL, Price PM: The p53 independent activation of transcription of p21WAF1/CIP1/SDT1 after acute renal failure. Am J Physiol 271:F1211–F1216, 1996 | PubMed | ISI | ChemPort |

Extra navigation

.
ADVERTISEMENT